Sepracor Norastemizole Onset Of Action Claim To Be Based On Chamber Data
Sepracor expects to secure a rapid onset of action claim for its antihistamine norastemizole based on environmental chamber studies being conducted.
You may also be interested in...
Sepracor's U.S. royalties from Allegra will be lower under an amendment to the company's existing arrangement with Hoechst Marion Roussel. As a settlement of all patent issues involving the non-sedating antihistamine, Hoechst received the Sepracor U.S. patent properties related to fexofenadine.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011